LY-255582
LY-255582 is a potent opioid receptor antagonist that has been studied for its potential therapeutic applications. It is a synthetic compound that interacts with the opioid receptor system in the brain and other parts of the body.
Pharmacology[edit | edit source]
LY-255582 acts primarily as an antagonist at the mu-opioid receptor (MOR), delta-opioid receptor (DOR), and kappa-opioid receptor (KOR). By blocking these receptors, LY-255582 can inhibit the effects of endogenous opioids and opioid drugs. This makes it a potential candidate for the treatment of opioid addiction and opioid overdose.
Mechanism of Action[edit | edit source]
The mechanism of action of LY-255582 involves its binding to the opioid receptors, preventing the activation of these receptors by endogenous ligands such as endorphins and enkephalins, as well as exogenous opioid drugs like morphine and heroin. This blockade can reduce the euphoric and analgesic effects of opioids, which is beneficial in treating addiction and overdose.
Therapeutic Applications[edit | edit source]
LY-255582 has been investigated for several therapeutic applications, including:
- Opioid addiction: By blocking the effects of opioids, LY-255582 may help in reducing cravings and withdrawal symptoms in individuals addicted to opioids.
- Opioid overdose: As an opioid receptor antagonist, LY-255582 can be used to reverse the life-threatening effects of opioid overdose, similar to naloxone.
- Pain management: Although primarily an antagonist, LY-255582's interaction with the opioid system may have implications for pain management, particularly in reducing opioid tolerance and dependence.
Research and Development[edit | edit source]
Research on LY-255582 is ongoing, with studies focusing on its efficacy, safety, and potential side effects. Clinical trials are necessary to fully understand its therapeutic potential and to determine the appropriate dosing regimens.
See Also[edit | edit source]
References[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
